Methods: The study population is made of woman patients aged 18 years and older diagnosed with HER2-positive BC at Instituto Nacional de Enfermedades Neoplásicas (INEN, Lima, Peru) during 2019–2021 and treated with at least one dose of subcutaneous trastuzumab. Here, ERBB2 is linked to breast cancer.